Advertisement

Diagnosis and Management of Tuberculous Pericarditis: What Is New?

  • Godsent IsiguzoEmail author
  • Elsa Du Bruyn
  • Patrick Howlett
  • Mpiko Ntsekhe
Pericardial Disease (AL Klein and CL Jellis, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Pericardial Disease

Abstract

Purpose of Review

This review provides an update on the immunopathogenesis of tuberculous pericarditis (TBP), investigations to confirm tuberculous etiology, the limitations of anti-tuberculous therapy (ATT), and recent efficacy trials.

Recent Findings

A profibrotic immune response characterizes TBP, with low levels of AcSDKP, high levels of γ-interferon and IL-10 in the pericardium, and high levels of TGF-β and IL-10 in the blood. These findings may have implications for future therapeutic targets. Despite advances in nucleic acid amplification approaches, these tests remain disappointing for TBP. Trials of corticosteroids and colchicine have had mixed results, with no impact on mortality, evidence of a reduction in rates of constrictive pericarditis and potential harm in those with advanced HIV. Small studies suggest that ATT penetrates the pericardium poorly. Given that there is a close association between high bacillary burden and mortality, a rethink about the optimal drug doses and duration may be required.

Summary

The high mortality and morbidity from TBP despite use of anti-tuberculous drugs call for researches targeting host-directed immunological determinants of treatment outcome. There is also a need for the identification of steps in clinical management where interventions are needed to improve outcomes.

Keywords

Tuberculous pericarditis Mycobacterium tuberculosis 

Notes

Compliance with Ethical Standards

Conflict of Interest

Godsent Isiguzo, Elsa Du Bruyn, Patrick Howlett, and Mpiko Ntsekhe declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Supplementary material

11886_2020_1254_MOESM1_ESM.jpg (67 kb)
Supplementary Figure 1 Posterior anterior chest x-ray view of the index patient showing a globular enlaged heart shadow (typical finding in pericardial effusion). (JPG 67 kb)
11886_2020_1254_MOESM2_ESM.gif (272 kb)
Supplementary Figure 2 An apical four chamber 2D echocardiography image of the index patient who presented in cardiac tamponade. Video shows large pericardial effusion with strands, swinging heart showing right ventricular collapse. (GIF 271 kb)
11886_2020_1254_MOESM3_ESM.gif (2.2 mb)
Supplementary Figure 3 Parasternal long axis (PLAX) 2D echocardiography image of the index patient displaying large pericardial effusion with obvious tachycardia and swinging of the heart with contraction and right ventricular collapse. (GIF 2260 kb)
11886_2020_1254_MOESM4_ESM.gif (613 kb)
Supplementary Figure 4 Subcostal view 2D echocardiography image of the index patient showing a thickened pericardium with effusion and swing heart. (GIF 613 kb)

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Van Der Meeren O, et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2018;379(17):1621–34. The article provides hope for eradication of tuberculosis by the finding that M72/AS01E provided 54.0% protection for M. tuberculosis–infected adults against active pulmonary tuberculosis disease, without evident safety concerns.CrossRefGoogle Scholar
  2. 2.
    Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. Aids. 2015;29(15):1987–2002.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Sagrista-Sauleda J, Permanyer-Miralda G, Soler-Soler J. Tuberculous pericarditis: ten year experience with a prospective protocol for diagnosis and treatment. J Am Coll Cardiol. 1988;11(4):724–8.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Mynors JM, Reichman B. Pericarditis--a five year study in the African. Cent Afr J Med. 1973;19(2):19–22.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect. 2005;133(3):393–9.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis. 2004;8(5):636–47.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Watch V, et al. The burden of presumed tuberculosis in hospitalized children in a resource-limited setting in Papua New Guinea: a prospective observational study. Int Health. 2017;9(6):374–8.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Obihara NJ, et al. Tuberculous pericardial effusions in children. J Pediatric Infect Dis Soc. 2018;7(4):346–9.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Hugo-Hamman CT, Scher H, De Moor MM. Tuberculous pericarditis in children: a review of 44 cases. Pediatr Infect Dis J. 1994;13(1):13–8.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Spodick DH. Tuberculous pericarditis. AMA Arch Intern Med. 1956;98(6):737–49.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Fail Rev. 2013;18(3):367–73.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Reuter H, et al. Characterization of the immunological features of tuberculous pericardial effusions in HIV positive and HIV negative patients in contrast with non-tuberculous effusions. Tuberculosis (Edinb). 2006;86(2):125–33.CrossRefGoogle Scholar
  13. 13.
    Matthews K, Ntsekhe M, Syed F, Scriba T, Russell J, Tibazarwa K, et al. HIV-1 infection alters CD4+ memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis. Eur J Immunol. 2012;42(1):147–57.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Shenje J, et al. Effect of prednisolone on inflammatory markers in pericardial tuberculosis: a pilot study. Int J Cardiol Heart Vasc. 2018;18:104–8.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Matthews K, Deffur A, Ntsekhe M, Syed F, Russell JB, Tibazarwa K, et al. A compartmentalized profibrotic immune response characterizes pericardial tuberculosis, irrespective of HIV-1 infection. Am J Respir Crit Care Med. 2015;192(12):1518–21.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Ntsekhe M, Matthews K, Wolske J, Badri M, Wilkinson KA, Wilkinson RJ, et al. Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) and galectin-3 levels in tuberculous pericardial effusion: implications for pathogenesis and prevention of pericardial constriction. Heart. 2012;98(17):1326–8.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Mnguni AT, Engel ME, Borkum MS, Mayosi BM. The effects of angiotensin converting enzyme inhibitors (ACE-I) on human N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) levels: a systematic review and meta-analysis. PLoS One. 2015;10(12):e0143338.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Pasipanodya JG, et al. Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality. EBioMedicine. 2015;2(11):1634–9.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Mayosi BM, et al. Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. BMC Infect Dis. 2006;6:2.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Schrire V. Experience with pericarditis at Groote Schuur Hospital, Cape Town: an analysis of one hundred and sixty cases studied over a six-year period. S Afr Med J. 1959;33:810–7.PubMedPubMedCentralGoogle Scholar
  21. 21.
    •• Mayosi BM, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–30 This landmark RCT was the first in Africa to investigate the place of steriod in tuberculous pericarditis. The results show that among HIV negative patients with TBP, prednisolone led to reduced incidence of constrictive pericarditis.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Ntsekhe M, Wiysonge CS, Gumedze F, Maartens G, Commerford PJ, Volmink JA, et al. HIV infection is associated with a lower incidence of constriction in presumed tuberculous pericarditis: a prospective observational study. PLoS One. 2008;3(6):e2253.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Syed FF, Mayosi BM. A modern approach to tuberculous pericarditis. Prog Cardiovasc Dis. 2007;50(3):218–36.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Noubiap JJ, et al. Epidemiology of pericardial diseases in Africa: a systematic scoping review. Heart. 2019;105(3):180–8.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Xie D, Cheng B, Sheng Y, Jin J. Diagnostic accuracy of adenosine deaminase for tuberculous pericarditis: a meta-analysis. Eur Rev Med Pharmacol Sci. 2015;19(22):4411–8.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Mayosi BM, et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr Med J. 2008;98(1):36–40.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation. 2005;112(23):3608–16.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–64.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Light RW. Pleural effusions. Med Clin North Am. 2011;95(6):1055–70.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Kyriakakis CG, Mayosi BM, de Vries E, Isaacs A, Doubell AF. An approach to the patient with suspected pericardial disease. SAMJ: South African Medical Journal. 2016;106(2):151–5.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Theron G, et al. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep. 2014;4:5658.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    • Kyriakakis CG. Tuberculous pericarditis: challenges and controversies in the modern era. SA Heart. 2016;13(2):104–11. One of the issues that delay early commencement of treatment in TBP is definitive diagnosis. The authors of the article introduce use of a pericardioscope for pericardial tissue collection to aid tissue diagnosis.Google Scholar
  33. 33.
    Corey GR, Campbell PT, van Trigt P, Kenney RT, O’Connor CM, Sheikh KH, et al. Etiology of large pericardial effusions. Am J Med. 1993;95(2):209–13.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Pandie S, et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-γ in a high burden setting: a prospective study. BMC Med. 2014;12(1):101.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    • Yu G, et al. Comparison between the diagnostic validities of Xpert MTB/RIF and interferon-gamma release assays for tuberculous pericarditis using pericardial tissue. PLoS One. 2017;12(12):e0188704. The World Health Organization has identified development of point of care diagnostic tools as the key in improvement of diagnosis and outcome in tuberculosis. The authors of this article show the high sensitivity of Xpert MTB/RIF in TBP. However, its non-superiority compared with older PCR is a drawback and calls for further investigations. PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Cegielski JP, Devlin BH, Morris AJ, Kitinya JN, Pulipaka UP, Lema LE, et al. Comparison of PCR, culture, and histopathology for diagnosis of tuberculous pericarditis. J Clin Microbiol. 1997;35(12):3254–7.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Pandie S, et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-gamma in a high burden setting: a prospective study. BMC Med. 2014;12:101.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Bian S, Zhang Y, Zhang L, Shi X and Liu X. Diagnostic Value of Interferon-gamma Release Assays on Pericardial Effusion for Diagnosis of Tuberculous Pericarditis. PLoS One. 2016;11:e0165008.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Burgess LJ, et al. The use of adenosine deaminase and interferon-gamma as diagnostic tools for tuberculous pericarditis. Chest. 2002;122(3):900–5.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Latouf S, Levetan B, Commerford P. Tuberculous pericardial effusion: analysis of commonly used diagnostic methods. S Afr Med J. 1996;86(Suppl):15.Google Scholar
  41. 41.
    • Liu C, et al. Diagnostic accuracy of interferon-gamma in pericardial effusions for tuberculous pericarditis: a meta-analysis. J Thorac Dis. 2018;10(2):854–60. The authors highlight the role of interferon gamma as a stand-alone test to exclude or diagnose TBP, which is a potential step in rapid diagnosis, with the high cost a drawback to its use in low–medium-income countries (LMICs). PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56(3):230–8.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Shenje J, et al. Poor penetration of antibiotics into pericardium in pericardial tuberculosis. EBioMedicine. 2015;2(11):1640–9.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Ristic AD, et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2014;35(34):2279–84.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Liebenberg J, van der Bijl P. A “vanishing”, tuberculous, pericardial effusion. Korean Circ J. 2016;46(6):879–81.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Reuter H, Burgess LJ, Louw VJ, Doubell AF. The management of tuberculous pericardial effusion: experience in 233 consecutive patients. Cardiovasc J S Afr. 2007;18(1):20–5.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Damasceno A, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012;172(18):1386–94.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Yankah C, et al. Cardiac surgery capacity in sub-Saharan Africa: quo vadis? Thorac Cardiovasc Surg. 2014;62(5):393–401.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 1987;2(8573):1418–22.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Strang JI, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. Qjm. 2004;97(8):525–35.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Wiysonge CS, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017;9:Cd000526.PubMedPubMedCentralGoogle Scholar
  52. 52.
    •• Mayosi BM, et al. Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 x 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. Am Heart J. 2013;165(2):109–15.e3. The authors of this Cochrane review provide a bird’s-eye view of interventions in the past 5 years focused on treatment of tuberculous pericarditis, and reveal areas of gaps in knowledge as well as potential research areas. PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409–14.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Liebenberg JJ, Dold CJ, Olivier LR. A prospective investigation into the effect of colchicine on tuberculous pericarditis. Cardiovasc J Afr. 2016;27(6):350–5.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    •• Wiyeh AB, et al. A systematic review of the efficacy and safety of intrapericardial fibrinolysis in patients with pericardial effusion. Int J Cardiol. 2018;250:223–8. The authors of this article posit that fibrin deposition could be central in the development of constrictive pericarditis and a potential target in its prevention. The ongoing Second Investigation of Management of Pericarditis (IMPI-2) Trial is designed to address this. PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Ntusi NA, Palkowski G, Samuels P, Moosa S, Ntsekhe M, Mayosi B. Cardiovascular magnetic resonance characterisation of pericardial and myocardial involvement in patients with tuberculous pericardial constriction with and without HIV co-infection. J Cardiovasc Magn Reson. 2016;18:Q29.  https://doi.org/10.1186/1532-429X-18-S1-Q29.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Godsent Isiguzo
    • 1
    • 2
    Email author
  • Elsa Du Bruyn
    • 3
  • Patrick Howlett
    • 3
    • 4
  • Mpiko Ntsekhe
    • 5
  1. 1.Department of MedicineUniversity of Cape TownCape TownSouth Africa
  2. 2.Department of MedicineFederal Teaching Hospital AbakalikiAbakalikiNigeria
  3. 3.Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of MedicineUniversity of Cape TownCape TownRepublic of South Africa
  4. 4.Department of MedicineImperial CollegeLondonUK
  5. 5.Division of Cardiology, Groote Schuur Hospital and Faculty of Health SciencesUniversity of Cape Town South AfricaCape TownSouth Africa

Personalised recommendations